Money A2Z Web Search

Search results

1. Results From The WOW.Com Content Network

2. Athersys (ATHX) Q4 Earnings: What's in Store for the Stock? - AOL

   www.aol.com/news/athersys-athx-q4-earnings-whats...

   During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.

3. Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study - AOL

   www.aol.com/news/athersys-athx-multistem-cell...

   Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.

4. Are Options Traders Betting on a Big Move in Athersys (ATHX ...

   www.aol.com/news/options-traders-betting-big...

   Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

5. What to watch at the Republican National Convention this week

   www.aol.com/watch-republican-national-convention...

   After surviving an assassination attempt in Pennsylvania, Donald Trump will be at the Republican National Convention in Milwaukee this week to accept his third consecutive GOP presidential nomination.

6. House Democrat: Trump assassination attempt ‘overtook’ Biden ...

   www.aol.com/news/house-democrat-trump...

   Rep. Greg Landsman (D-Ohio) on Tuesday suggested he has backed away from publicly calling on President Biden to step out of the 2024 race, stating the assassination attempt against former ...

7. Implied Volatility Surging for Athersys (ATHX) Stock Options

   www.aol.com/news/implied-volatility-surging...

   For premium support please call: 800-290-4726 more ways to reach us

8. Athersys, Inc. (ATHX) Upgraded to Buy: Here's Why - AOL

   www.aol.com/news/athersys-inc-athx-upgraded-buy...

   For premium support please call: 800-290-4726 more ways to reach us

9. Athersys (ATHX) Down as Ischemic Stroke Study Fails to ... - AOL

   www.aol.com/news/athersys-athx-down-ischemic...

   While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.